New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma
PHASE2CompletedINTERVENTIONAL
Enrollment
90
Participants
Timeline
Start Date
April 30, 1993
Study Completion Date
January 31, 2002
Conditions
Ewing's SarcomaNeuroblastomaRhabdomyosarcoma
Interventions
DRUG
ADR-529
DRUG
Topotecan
DRUG
G-CSF
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001335 - New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | Biotech Hunter | Biotech Hunter